Experience
Rooam to Be Acquired by American Express
June 21, 2024
Cooley advised Rooam, a contactless payment platform that integrates directly into existing point of sale systems without adding extra hardware, on its agreement to be acquired by American Express (NYSE: AXP), a globally integrated payments company providing customers with access to products, insights and experiences that enrich lives and build business success.
Related contacts
Related Practices & Industries
Freshworks Agrees to Acquire Device42
May 3, 2024
Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.
Related contacts
Related Practices & Industries
Rubicon Technology Partners Announces Strategic Majority Investment in Vimly Benefit Solutions
February 13, 2024
Cooley advised Rubicon Technology Partners – a Boulder, Colorado-based private equity firm focused exclusively on investing in and growing software companies – on its majority strategic investment in Vimly Benefit Solutions, a leader in the benefits administration space.
Related contacts
Related Practices & Industries
RayzeBio Signs Approximately $4.1 Billion Acquisition Agreement With Bristol Myers Squibb
December 26, 2023
Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.
Related contacts
Related Practices & Industries
RayzeBio Announces Upsized $357.6 Million IPO
September 19, 2023
Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.
Related contacts
Related Practices & Industries
Admissions and credentials
California
New York